BAN2401-G000-201: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BAN2401 in subjects with early Alheimer's disease.
- 50 Years - 90 Years
- Eisai Pharmaceuticals
- Last Updated:
- Study HIC#: